Anti-PD-L1 antibodies
Anti-PD-L1 antibodies are disclosed. Also disclosed are pharmaceutical compositions comprising such antibodies, and uses and methods using the same.
1. An isolated nucleic acid encoding an antibody or antigen binding fragment that specifically binds to human PD-L1, comprising:
(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:21
HC-CDR2 having the amino acid sequence of SEQ ID NO:22
HC-CDR3 having the amino acid sequence of SEQ ID NO:25; and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:18
LC-CDR2 having the amino acid sequence of SEQ ID NO:19
LC-CDR3 having the amino acid sequence of SEQ ID NO:20.
2. The isolated nucleic acid according to claim 1 , wherein the antibody or antigen binding fragment comprises:
a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:8 or SEQ ID NO:35; and
a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:4.
3. The isolated nucleic acid according to claim 1 , wherein the antibody or antigen binding fragment comprises a single-chain Fv (scFv) comprising the VH region and the VL region.
4. The isolated nucleic acid according to claim 1 , wherein the antibody or antigen binding fragment comprises a constant region from human IgG1.
5. A vector comprising a nucleic acid encoding an antibody or antigen binding fragment that specifically binds to human PD-L1, comprising:
(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:21
HC-CDR2 having the amino acid sequence of SEQ ID NO:22
HC-CDR3 having the amino acid sequence of SEQ ID NO:25; and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:18
LC-CDR2 having the amino acid sequence of SEQ ID NO:19
LC-CDR3 having the amino acid sequence of SEQ ID NO:20.
6. The vector according to claim 5 , wherein the antibody or antigen binding fragment comprises:
a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:8 or SEQ ID NO:35; and
a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:4.
7. The vector according to claim 5 , wherein the antibody or antigen binding fragment comprises a single-chain Fv (scFv) comprising the VH region and the VL region.
8. The vector according to claim 5 , wherein the antibody or antigen binding fragment comprises a constant region from human IgG1.
9. The vector according to claim 5 , wherein the vector is a viral vector.